Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer

Oncotarget

Volumn 6, Issue 17, 2015, Pages 15348-15361

  Hu, Meichun ^a   Peng, Shihong ^a   He, Yundong ^a   Qin, Min ^a   Cong, Xiaonan ^a   Xing, Yajing ^a   Liu, Mingyao ^a,b   Yi, Zhengfang ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Hormone refractory PCa; Lycorine; STAT3 signaling; Tumor growth and metastasis

Indexed keywords

AMARYLLIDACEAE ALKALOID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; LYCORINE; PHENANTHRIDINE DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MOUSE; NEOPLASM METASTASIS; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHENANTHRIDINES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84934343478     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3610     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
2. Silvestris N, Leone B, Numico G, Lorusso V, De Lena M. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology. 2005; 69:273-282.
3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:252-271.
4. Jimenez A, Santos A, Alonso G, Vazquez D. Inhibitors of protein synthesis in eukarytic cells. Comparative effects of some amaryllidaceae alkaloids. Biochimica et biophysica acta. 1976; 425:342-348.
5. Nair JJ, van Staden J. Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. Natural product communications. 2014; 9:1193-1210.
6. Hwang YC, Chu JJ, Yang PL, Chen W, Yates MV. Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antiviral research. 2008; 77:232-236.
7. Sener B, Orhan I, Satayavivad J. Antimalarial activity screening of some alkaloids and the plant extracts from Amaryllidaceae. Phytotherapy research: PTR. 2003; 17:1220-1223.
8. Mikami M, Kitahara M, Kitano M, Ariki Y, Mimaki Y, Sashida Y, Yamazaki M, Yui S. Suppressive activity of lycoricidinol (narciclasine) against cytotoxicity of neutrophil-derived calprotectin, and its suppressive effect on rat adjuvant arthritis model. Biological & pharmaceutical bulletin. 1999; 22:674-678.
9. Nair JJ, Bastida J, Codina C, Viladomat F, van Staden J. Alkaloids of the South African Amaryllidaceae: a review. Natural product communications. 2013; 8:1335-1350.
10. Tamplin OJ, Durand EM, Carr LA, Childs SJ, Hagedorn EJ, Li P, Yzaguirre AD, Speck NA, Zon LI. Hematopoietic stem cell arrival triggers dynamic remodeling of the perivascular niche. Cell. 2015; 160:241-252.
11. Liu J, Hu WX, He LF, Ye M, Li Y. Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis. FEBS letters. 2004; 578:245-250.
12. Li Y, Liu J, Tang LJ, Shi YW, Ren W, Hu WX. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest. Oncology reports. 2007; 17:377-384.
13. Liu J, Li Y, Tang LJ, Zhang GP, Hu WX. Treatment of lycorine on SCID mice model with human APL cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2007; 61:229-234.
14. Liu J, Hu JL, Shi BW, He Y, Hu WX. Up-regulation of p21 and TNF-alpha is mediated in lycorine-induced death of HL-60 cells. Cancer cell international. 2010; 10:25.
15. Liu XS, Jiang J, Jiao XY, Wu YE, Lin JH, Cai YM. Lycorine induces apoptosis and down-regulation of Mcl-1 in human leukemia cells. Cancer letters. 2009; 274:16-24.
16. Lamoral-Theys D, Andolfi A, Van Goietsenoven G, Cimmino A, Le Calve B, Wauthoz N, Megalizzi V, Gras T, Bruyere C, Dubois J, Mathieu V, Kornienko A, Kiss R, Evidente A. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. Journal of medicinal chemistry. 2009; 52:6244-6256.
17. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer research. 2007; 67:2497-2507.
18. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000; 19:6613-6626.
19. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer research. 2002; 62:6659-6666.
20. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117:927-939.
21. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer research. 2007; 67:9066-9076.
22. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:7391-7396.
23. Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, Park CG, Lee HY. A ROS/STAT3/HIF-1alpha signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. The Prostate. 2014; 74:528-536.
24. Aloysius H, Hu L. Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer. Medicinal research reviews. 2015; 35:554-585.
25. Jorvig JE, Chakraborty A. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity. Anti-cancer drugs. 2015; 26:160-166.
26. Claperon A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chretien Y, Merabtene F, Frazao A, Paradis V, Housset C, Guedj N, Fouassier L. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. Journal of hepatology. 2014; 61:325-332.
27. Misra A, Pandey C, Sze SK, Thanabalu T. Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). PloS one. 2012; 7:e49766.
28. Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral oncology. 2013; 49:287-292.
29. Sakuma K, Aoki M, Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:7776-7781.
30. Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34:2497-2506.
31. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. The Journal of biological chemistry. 2008; 283:14665-14673.
32. Valdespino V, Tsagozis P, Pisa P. Current perspectives in the treatment of advanced prostate cancer. Medical oncology. 2007; 24:273-286.
33. Kronig M, Walter M, Drendel V, Werner M, Jilg CA, Richter AS, Backofen R, McGarry D, Follo M, Schultze-Seemann W, Schule R. Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity. Oncotarget. 2015; 6:1302-1314.
34. Pouessel D, Serrate C, Gauthier H, Hennequin C, Culine S. [Chemotherapy in castrate-resistant metastatic prostate cancer]. La Revue du praticien. 2013; 63:511-514.
35. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). International journal of oncology. 2007; 30:233-245.
36. Adhami VM, Mukhtar H. Polyphenols from green tea and pomegranate for prevention of prostate cancer. Free radical research. 2006; 40:1095-1104.
37. Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert opinion on investigational drugs. 2006; 15:1191-1200.
38. Gupta S. Prostate cancer chemoprevention: current status and future prospects. Toxicology and applied pharmacology. 2007; 224:369-376.
39. El-Tanani MK, Green CD. Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. The Journal of steroid biochemistry and molecular biology. 1997; 60:269-276.
40. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010; 29:4947-4958.
41. Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PloS one. 2011; 6:e27720.
42. McNulty J, Nair JJ, Singh M, Crankshaw DJ, Holloway AC, Bastida J. Cytochrome P40 3A4 inhibitory activity studies within the lycorine series of alkaloids. Natural product communications. 2010; 5:1195-1200.
43. Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Oncotarget. 2015; 6:1507-1518.
44. Zhang T, Chen Y, Li J, Yang F, Wu H, Dai F, Hu M, Lu X, Peng Y, Liu M, Zhao Y, Yi Z. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer. Neoplasia. 2014; 16:665-677.
45. Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X, Liu M. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Molecular cancer therapeutics. 2012; 11:277-287.
46. Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, Yang Z, Zhang Y, Shi T, Luo J, Liu M. Inhibition of breast cancer metastases by a novel inhibitor of TGFbeta receptor 1. Journal of the National Cancer Institute. 2013; 105:47-58.
47. Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, Horne D, Morgan R, Wakabayashi M, Dellinger TH, Han ES, Yim JH, et al. Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer. Molecular cancer therapeutics. 2014; 13:3037-3048.
48. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer research. 2008; 68:9024-9032.